Novartis Sets Dates For Canine Atopic Dermatitis CPD

Novartis Animal Health, manufacturer of Atopica®, is presenting a series of free evening CPD seminars on the practical management of canine atopic dermatitis. Westie with atopic dermatitis The speakers for these interactive and practical sessions for vets are leading dermatologists Tim Nuttall, BSc, BVSc, PhD, CertVD, CBiol, MIBiol, MRCVS, senior lecturer in veterinary dermatology at Liverpool University and Rutland House Referrals’ Stephen Shaw, BVetMed, PhD, CertSAD, MRCVS. Agnès Delauche, senior brand manager at Novartis, said: “Research carried out by Novartis has shown that 86 per cent of owners whose dogs were diagnosed with atopic dermatitis were frustrated with the condition. In addition, 44 per cent of owners left their original veterinary surgeon in search of a solution for their dog’s atopy. It can be a long and exasperating problem for both the dog and the owner, so it’s critical that a timely diagnosis and effective treatment regime are provided. We hope that the expertise and vast experience of our speakers will assist veterinary professionals in managing this condition.” The evening sessions count for two hours of CPD and begin at 8pm, with a finger buffet available from 7.30pm. The seminars commence in April with Dr Tim Nuttall:

• Tuesday 21st April - The Hilton Hotel, Bromsgrove, Birmingham
• Wednesday 22nd April - The Ramada Hotel, Belfast, N. Ireland
• Thursday 23rd April - The Macdonald Inchyra Grange Hotel, Falkirk, Stirlingshire

Followed by further dates with Dr Stephen Shaw:

• Wednesday 29th April - The Thistle Hotel, Saint Helens, Merseyside
• Thursday 30th April - The Aztec Hotel & Spa, Almondsbury, Bristol.

Spaces are limited and will be allocated on a first-come-first-serve basis, so to secure a place, contact Lynsey Greggain on +44 207 424 3370.

More from

• Nettex Equine help horses perform, look and feel their best with new V.I.P range
• Systematic review does not support use of angiotensin-converting enzyme inhibitors in dogs with preclinical myxomatous mitral disease and cardiomegaly
• SPILLERS fuels performance potential with new competition range
• Vet Aquadent® FR3SH™ Now Includes Innovative FR3SH™ Technology
• Epidemiological study identifies novel breed associations for Cushing’s syndrome in dogs